Topical imiquimod for the treatment of keratoacanthomas

European Journal of Dermatology

Volumn 18, Issue 5, 2008, Pages 590-591

  Calista, Donato ^a   Morri, Massimo ^b  

^a BUFALINI HOSPITAL   (Italy)

^b Ospedale Per Gli Infermi   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; IMIQUIMOD;

AGED; BEDTIME DOSAGE; BLEEDING; BURNING SENSATION; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; EPITHELIUM CELL; FEMALE; HEART ARRHYTHMIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KERATOACANTHOMA; LETTER; MALE; SKIN BIOPSY; SKIN NODULE; TREATMENT DURATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AGED; AMINOQUINOLINES; FEMALE; HUMANS; KERATOACANTHOMA; MALE;

EID: 52649149191     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2008.0476     Document Type: Letter

References (6)

1. Karaa A, Kochemoune A. Keratoacanthoma: a tumor in search of a classification. Int J Dermatol 2007; 46: 671-8.
2. Quatresooz P, Pierard-Franchimont G, Paquet P, Hubert P, Delvenne P, Pierard GE. Crossroad between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues. Eur J Dermatol 2008; 18: 6-10.
3. Peris K, Micantonio T, Fargnoli MC. Successful treatment of keratoacanthoma and actinic keratoses with imiquimod 5% cream. Eur J Dermatol 2003; 13: 413-4.
4. Di Lernia V, Ricci C, Albertini G. Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream. J Eur Acad Dermatol Venereol 2004; 18: 626-9.
5. Garland, SM. Imiquimod. Curr Opin Infect Dis 2003; 16: 85-9.
6. Schon M, Bang AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138-49.